# ALCYONE (NCT02195479)

> A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma

No report yet. It can be ordered.

- Drugs tested: daratumumab
- Indication: transplant-ineligible newly diagnosed multiple myeloma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02195479
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Janssen Research & Development, LLC
- Conditions: Multiple Myeloma
- Interventions: Velcade; Melphalan; Prednisone; Daratumumab IV; Dexamethasone; Daratumumab SC
- Enrollment: 706
- Primary outcome: Progression Free Survival (PFS)

## Indexed commentary on ALCYONE so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 47 posts on X
- 19 YouTube videos
- 9 podcast episodes

## Order

Deep, $1,950 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=alcyone-nct02195479

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02195479", "email": "<work email>"}; the inbox owner confirms by the emailed link.